Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

• Sponsor: University of Southern California (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT06067295
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 150
• Locations: 2
• Anticipated Duration (Months): 48
• Patients Per Site: 75
• Patients Per Site Per Month: 1.6

Study Details

Study Description

Brief Summary

This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.

Condition or Disease	Intervention/Treatment	Phase
Prostate Carcinoma	Other: Non-Interventional Study

Detailed Description

PRIMARY OBJECTIVE:

1. To create an annotated biorepository with prospectively collected blood and urine samples from men with advanced prostate cancer.

OUTLINE: This is an observational study.

Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 150 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
• Actual Study Start Date: Feb 21, 2023
• Anticipated Primary Completion Date: Feb 21, 2026
• Anticipated Study Completion Date: Feb 21, 2027

Arms and Interventions

Arm	Intervention/Treatment
Observational Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.	Other: Non-Interventional Study; Non-interventional study

Outcome Measures

Primary Outcome Measures

1. Collection of biological specimens and clinical data for future research related to prostate cancer. [Up to 5 years]

   The objective of this study is to create a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• • Men of all racial and ethnic groups 18 years of age or older

• Men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy)

• Prior participation on clinical trials is allowed

Exclusion Criteria:

• • Inability to give informed consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Los Angeles County-USC Medical Center	Los Angeles	California	United States	90033
2	USC / Norris Comprehensive Cancer Center	Los Angeles	California	United States	90033

Sponsors and Collaborators

• University of Southern California
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Amir Goldkorn, MD, University of Southern California

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University of Southern California
• ClinicalTrials.gov Identifier: NCT06067295
• Other Study ID Numbers: 4P-22-2; NCI-2023-01434; 4P-22-2; P30CA014089
• First Posted: Oct 4, 2023
• Last Update Posted: Oct 10, 2023
• Last Verified: Oct 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Additional relevant MeSH terms: Prostatic Neoplasms

Study Results

No Results Posted as of Oct 10, 2023